TargetMol

MK-2206

Product Code:
 
TAR-T62609
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T62609-5mg5mg£1,167.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T62609-50mg50mg£2,307.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T62609-100mg100mg£2,898.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
MK-2206 is an orally active, highly selective, metabotropic Akt inhibitor that acts on Akt1 (IC50: 8 nM), Akt2 (IC50: 12 nM) and Akt3 (IC50: 65 nM). Many breast cancer cell lines, PIK3CA mutants and PTEN-losing cell lines are sensitive to MK-2206, which has anti-cancer effects.
CAS:
1032349-77-1
Molecular Weight:
443.94
Purity:
0.98
SMILES:
Cl.NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1

References

Liang J, Zhao G, Bian Y, et al.HNF4G increases cisplatin resistance in lung adenocarcinoma via the MAPK6/Akt pathway.PeerJ.2023, 11: e14996. Sun R, Ge W, Zhu Y, et al.Proteomic Dynamics of Breast Cancer Cell Lines Identifies Potential Therapeutic Protein Targets.Molecular & Cellular Proteomics.2023: 100602. Xie X, Zhang W, Zhou X, et al.Low doses of IFN-? maintain self-renewal of leukemia stem cells in acute myeloid leukemia.Oncogene.2023: 1-13. Yang N, Fan Z, Sun S, et al.Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation.European Journal of Medicinal Chemistry.2023: 115857.